EU Policy Mirrors US Biomanufacturing Reshoring Through Its Biotech Act II

Introduction

The European Union is moving to strengthen its position in industrial biotechnology and biomanufacturing through the planned EU Biotech Act II, a policy initiative focused on helping biotechnology companies move from research and innovation to commercial-scale production.

The initiative reflects a broader global shift toward strengthening domestic manufacturing capacity and building more resilient supply chains. While the United States has increasingly emphasized reshoring and domestic production across strategic industries, the EU is pursuing a similar objective through policy, investment, market development, and regulatory measures.

The European Commission has identified Biotech Act II as a key 2026 initiative aimed at creating an environment in which industrial biotechnology and biomanufacturing can scale within Europe.

What Is the EU Biotech Act II?

The European Commission divided its broader biotechnology policy agenda into two parts.

Biotech Act I primarily addresses health biotechnology and focuses on areas such as regulatory simplification and improving the environment for innovative health technologies.

Biotech Act II, which is expected to focus on industrial biotechnology, biomanufacturing, and horizontal enabling conditions, is intended to address the gap between scientific innovation and industrial-scale production.

The European Commission has already begun gathering feedback from companies, researchers, industry experts, and other stakeholders to identify the main barriers facing industrial biotechnology and biomanufacturing in Europe.

Why Europe Is Focusing on Biomanufacturing

Europe has strong research capabilities and a significant biotechnology ecosystem, but translating scientific discoveries into large-scale manufacturing remains a challenge.

Industry organizations argue that regulatory fragmentation, duplication between jurisdictions, limited market incentives, and difficulties in securing scale-up investment can slow the commercialization of biotechnology.

A joint industry statement published by nearly 40 European, national, and regional organizations described Biotech Act II as an important step toward creating the conditions needed for biomanufacturing scale-up and market deployment in Europe.

The European Commission has similarly identified industrial biotechnology as a potential tool for reducing dependence on virgin fossil feedstocks while strengthening resilience and supporting the transition toward a circular economy.

The Reshoring Connection With the United States

The comparison with U.S. reshoring is particularly relevant because both approaches are responding to concerns about industrial dependency and supply-chain resilience.

In the United States, reshoring policies have increasingly focused on bringing strategic manufacturing capabilities back to domestic facilities and reducing dependence on overseas production.

Europe is approaching the issue differently. Rather than relying primarily on tariffs or direct trade restrictions, the EU's Biotech Act II is designed to make Europe a more attractive location for biotechnology investment and manufacturing.

The common objective is nevertheless similar: retain strategic industrial capacity, strengthen domestic supply chains, and reduce vulnerability to external disruptions.

Building Demand for European Biomanufacturing

One of the most important elements being considered for Biotech Act II is the creation of lead markets and stronger demand for products manufactured using biotechnology.

The European Commission has specifically identified demand generation and greater predictability for investors as possible components of the initiative.

This matters because building a biotechnology plant requires substantial capital and long-term confidence.

If companies believe that European customers will purchase bio-based chemicals, materials, ingredients, fuels, or other products, they are more likely to invest in local production capacity.

Policy can therefore influence the entire investment cycle—from laboratory research and pilot plants to commercial facilities.

Moving From Innovation to Industrial Scale

One of Europe's biggest challenges is the so-called scale-up gap.

A technology can demonstrate strong performance in a laboratory or pilot environment but still struggle to become commercially competitive.

Biotech Act II is intended to help address this transition by creating an environment that supports:

• Pilot and demonstration projects

• Commercial-scale biomanufacturing

• Investment in production facilities

• Faster market access

• Regulatory predictability

• Development of European supply chains

• Stronger links between research and industry

• Demand for bio-based products

Industry groups have argued that Europe needs a dedicated framework that goes beyond scientific research and focuses specifically on industrial deployment.

Strategic Importance for Chemical Manufacturing

The implications extend well beyond biotechnology companies.

Industrial biotechnology can provide alternative production pathways for chemicals, materials, enzymes, ingredients, and other industrial products.

For chemical manufacturers, this could eventually create new options for sourcing carbon and other raw materials.

Instead of relying exclusively on fossil-based feedstocks, manufacturers could increasingly use:

• Biomass-derived inputs

• Fermentation-based feedstocks

• Recycled carbon

• Industrial CO₂

• Bio-based intermediates

• Other renewable biological resources

This aligns with the EU's broader objective of reducing dependence on virgin fossil resources while developing a more circular industrial economy.

Competition With the US, China and Other Regions

Europe is not developing its biomanufacturing strategy in isolation.

Industry stakeholders have pointed to the growing emphasis on biomanufacturing in the United States, China, and India as evidence that Europe needs to accelerate its own industrial capabilities.

China, for example, has incorporated biomanufacturing into its strategic industrial planning, while the United States has been encouraging investment in domestic manufacturing and advanced industrial technologies.

For Europe, the challenge is therefore not simply to produce more biotechnology research. It is to ensure that successful technologies are commercialized and manufactured within the region.

Investment and Supply-Chain Implications

A successful Biotech Act II could have important implications for investment decisions.

If Europe can reduce regulatory uncertainty and create stronger demand for bio-based products, companies may become more willing to establish pilot plants, demonstration facilities, and commercial manufacturing sites within the EU.

This could generate a multiplier effect across the supply chain.

Greater biomanufacturing capacity could increase demand for:

• Fermentation equipment

• Bioreactors

• Industrial enzymes

• Process-control systems

• Specialty chemicals

• Renewable feedstocks

• Engineering services

• Laboratory technologies

• Industrial infrastructure

As production capacity expands, Europe could gradually develop a more complete domestic biomanufacturing ecosystem.

A Policy Shift Toward Industrial Competitiveness

The proposed legislation represents a broader change in how Europe approaches biotechnology.

The emphasis is moving from simply supporting scientific innovation toward ensuring that innovation produces industrial and economic value.

The European Commission has explicitly described the wider biotech agenda as an effort to translate scientific excellence into industrial capacity and strengthen Europe's competitiveness.

This is particularly important for startups and scale-ups that often face significant costs when moving from laboratory development to commercial production.

Challenges Ahead

Despite its potential, Biotech Act II will face several challenges.

Policy alone cannot guarantee that European biomanufacturing will become globally competitive. Companies will still need access to affordable energy, skilled workers, capital, infrastructure, feedstocks, and customers.

Europe will also need to balance faster commercialization with its existing environmental, safety, and regulatory standards.

Another challenge will be ensuring that the framework works for both large industrial companies and smaller biotechnology startups.

The success of the initiative will ultimately depend on whether it can reduce the gap between European scientific capability and European manufacturing capacity.

What This Means for the Chemical Market

For chemical producers and buyers, the development of Biotech Act II is worth monitoring because it could gradually change the geography of chemical feedstock production.

If European biomanufacturing capacity expands, chemical buyers could gain access to additional regional sources of bio-based and low-carbon intermediates.

This could create greater diversification alongside traditional petrochemical supply chains and potentially reduce exposure to disruptions in overseas feedstock markets.

For procurement teams, the longer-term implication is that biotechnology may increasingly become a feedstock and manufacturing strategy rather than simply a sustainability initiative.

Conclusion

The EU's planned Biotech Act II represents a strategic attempt to strengthen Europe's industrial biotechnology and biomanufacturing capabilities.

While the policy approach differs from U.S. reshoring measures, both reflect the same broader economic reality: governments increasingly want critical technologies and manufacturing capabilities to be developed closer to home.

For Europe, the priority is to convert its strong scientific base into commercial production, resilient supply chains, investment, and industrial competitiveness.

If Biotech Act II successfully creates stronger markets, improves regulatory predictability, and accelerates scale-up, it could help establish Europe as a more competitive global hub for biomanufacturing—and create new opportunities across the chemical, materials, food, pharmaceutical, and industrial biotechnology sectors.